Bigfoot and Abbott: A Match Made in Heaven? An Interview with Bigfoot Biomedical CEO Jeffrey Brewer

article image

Bigfoot Biomedical’s recent deal to integrate Abbott’s FreeStyle Libre glucose sensor technology into its automated insulin delivery system is a major step toward Bigfoot’s goal of creating the most patient-friendly AP system possible. In this Q&A, Bigfoot CEO Jeffrey Brewer lays out the rationale for the deal and how it fits into the company’s long-term, patient-centric vision.

Collaboration is the name of the game in the diabetes device field these days, and the past few months have certainly followed that trend, with a number of new deals announced recently (see Figure 1).


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: